Firefighters show higher rates of glioma-linked SBS42 mutational signatures associated with haloalkane exposure, suggesting ...

https://www.uksh.de/Das+UKSH/Presse/Presseinformationen/2025/Personalisierte+The... https://tu-dresden.de/med/mf/die-fakultaet/newsuebersicht/personalisierte-therap ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] Technology appraisal guidance 10 September 2025 Seladelpar for ...

The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 in trials for a form of brain cancer ...

Vorasidenib is a medication specifically designed for patients whose gliomas have mutations in the IDH1 or IDH2 genes. Instead of using broad methods to kill cancer cells (as chemotherapy or radiation ...

For patients who have something known as an IDH1 or IDH2 mutation, promising new drugs called IDH inhibitors may be an option. Gliomas are a group of brain tumors that vary in severity, from ...